Šveice - vācu - Swissmedic (Swiss Agency for Therapeutic Products)

accord healthcare ag - posaconazolum - magensaftresistente tablette - posaconazolum 100 mg, acidi methacrylici und ethylis acrylatis polymerisatum 1:1, triethylis citras, xylitolum, hydroxypropylcellulosum, cellulosum microcristallinum, silica colloidalis anhydrica, carmellosum natricum nur zusammen gehalten, natrii stearylis fumaras, e 310, Überzug: poly(alkohol vinylicus), macrogolum 3350, talkum, e 171, e 172 (gelb), für compresso haze endwerte. natrium 1,25 mg. - pilzinfektionen - synthetika

Šveice - vācu - Swissmedic (Swiss Agency for Therapeutic Products)

accord healthcare ag - posaconazolum - suspension zum einnehmen - posaconazolum 200 mg, macrogolglyceroli hydroxystearas 25 mg, natrii citras dihydricus, acid citricum monohydricum, dimeticonum, silica colloidalis hydrica, methylcellulosum, säure sorbicum, polysorbatum 65, macrogoli stearas, xanthani kaugummi, traubenzucker-flüssigkeit, 1.75 g, glycerolum, säure benzoicum < 12 µg, säure sulfuricum, sind (erdbeeraroma), propylenglycolum 10.86 mg, e 171, e-211 11.4 mg, aqua purificata, um die suspension für 5 ml endwerte., natrium 2.52 mg. - antimykotikum - synthetika

Austrija - vācu - AGES (Agentur für Gesundheit und Ernährungssicherheit)

accord healthcare b.v. - daptomycin -

Austrija - vācu - AGES (Agentur für Gesundheit und Ernährungssicherheit)

accord healthcare b.v. - daptomycin -

Eiropas Savienība - vācu - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastische mittel - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Eiropas Savienība - vācu - EMA (European Medicines Agency)

accord healthcare s.l.u. - abirateronacetat - prostata-neoplasmen - endokrine therapie - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Austrija - vācu - AGES (Agentur für Gesundheit und Ernährungssicherheit)

accord healthcare b.v. - aripiprazol -

Austrija - vācu - AGES (Agentur für Gesundheit und Ernährungssicherheit)

accord healthcare b.v. - aripiprazol -

Austrija - vācu - AGES (Agentur für Gesundheit und Ernährungssicherheit)

accord healthcare b.v. - aripiprazol -

Austrija - vācu - AGES (Agentur für Gesundheit und Ernährungssicherheit)

accord healthcare b.v. - aripiprazol -